Retrobulbar injection of amphotericin B using intravenous cannula for post-COVID-19 rhino-orbital mucormycosis.

Abstract

Rhino-orbital mucormycosis has seen a huge resurgence in patients post COVID-19 infection. In patients with minimal orbital disease and especially with preserved vision, retrobulbar injections of amphotericin B can be of great help in controlling the disease. Instead of giving daily injections of amphotericin B using needles every time, we used an 18-gauge intravenous (IV) cannula with injection port and suture holes to deliver the amphotericin into the orbital space for a period of 5 days. Patients were more compliant and less distressed with this method compared with being given an injection with a needle daily. We got a good response in terms of orbital disease regression with this method. In our review of the literature, we did not come across any such case of amphotericin B injection using an IV cannula. Injection of amphotericin B into the orbit using an IV cannula is a viable and easy treatment option for cases of rhino-orbital mucormycosis.

• Authors: Ramesh Murthy, Aadhyaa Bagchi, Yogita Gote, Sanjay Desai
• Journal: Indian journal of ophthalmology (Indian J Ophthalmol) Vol. 70 Issue 1 Pg. 302-305 (Jan 2022) ISSN: 1998-3689 [Electronic] India
• PMID: 34937263 (Publication Type: Case Reports)

Chemical References

• Antifungal Agents
• Amphotericin B

Topics

• Amphotericin B
• Antifungal Agents (therapeutic use)
• COVID-19
• Cannula
• Eye Infections, Fungal (diagnosis, drug therapy)
• Humans
• Mucormycosis (diagnosis, drug therapy)
• Orbital Diseases (diagnosis, drug therapy)
• SARS-CoV-2